Literature DB >> 11155801

The cytokine-HPA axis circuit contributes to prevent or moderate autoimmune processes.

A del Rey1, H O Besedovsky.   

Abstract

There is evidence that an immunoregulatory circuit integrated by immune-derived cytokines and the hypothalamus-pituitary-adrenal (HPA) axis operates during certain pathological conditions. For example, it has been shown that IL-1 is the main mediator of the increase in ACTH and corticosterone blood levels detected in models of viral infection and bacterial endotoxins. This endocrine response has protective effects during septic shock. In experimental models of tumors, there are also clear indications that the increase in glucocorticoid levels detected during the growth of a lymphoma is mediated by immune-derived products and contributes to the inhibition of the inflammatory response. The disruption of the cytokine-HPA axis circuit can predispose to autoimmunity. This has been shown in animal models of spontaneous autoimmune thyroiditis, lupus-like disease, and experimental arthritis. More recently, it has been shown that the proper operation of this circuit contributes to preventing or moderating autoimmunity. The recovery of animals from experimental autoimmune encephalomyelitis (EAE) is clearly dependent on an increase in endogenous glucocorticoid levels. It has been recently shown that this endocrine response is, at least in part, triggered by the immune response to the encephalitogenic antigen and mediated by the endogenous IL-1 produced during the disease. These examples support the concept that the cytokine-HPA circuit plays a protective role during certain pathologies and that its disruption can lead to predisposition to or aggravation of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155801     DOI: 10.1007/s003930070015

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  8 in total

Review 1.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

2.  The role of IL-1β in nicotine-induced immunosuppression and neuroimmune communication.

Authors:  Seddigheh Razani-Boroujerdi; Raymond J Langley; Shashi P Singh; Juan Carlos Pena-Philippides; Jules Rir-sima-ah; Sravanthi Gundavarapu; Neerad C Mishra; Mohan L Sopori
Journal:  J Neuroimmune Pharmacol       Date:  2011-06-14       Impact factor: 4.147

Review 3.  The short-term stress response - Mother nature's mechanism for enhancing protection and performance under conditions of threat, challenge, and opportunity.

Authors:  Firdaus S Dhabhar
Journal:  Front Neuroendocrinol       Date:  2018-03-26       Impact factor: 8.606

Review 4.  Effects of stress on immune function: the good, the bad, and the beautiful.

Authors:  Firdaus S Dhabhar
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

5.  Environmental context differentially affects behavioral, leukocyte, cortisol, and interleukin-6 responses to low doses of endotoxin in the rhesus monkey.

Authors:  Auriel A Willette; Gabriele R Lubach; Christopher L Coe
Journal:  Brain Behav Immun       Date:  2007-03-01       Impact factor: 7.217

6.  Interleukin-1 receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the spleen.

Authors:  Harald Engler; Michael T Bailey; Andrea Engler; LaTonia M Stiner-Jones; Ning Quan; John F Sheridan
Journal:  Psychoneuroendocrinology       Date:  2007-11-26       Impact factor: 4.905

7.  Hepatic expression of metallothionein I/II, glycoprotein 96, IL-6, and TGF- β in rat strains with different susceptibilities to experimental autoimmune encephalomyelitis.

Authors:  Tanja Grubić-Kezele; Gordana Blagojević Zagorac; Hrvoje Jakovac; Robert Domitrović; Cedomila Milin; Biserka Radošević-Stašić
Journal:  Clin Dev Immunol       Date:  2013-12-04

Review 8.  Balneotherapy, Immune System, and Stress Response: A Hormetic Strategy?

Authors:  Isabel Gálvez; Silvia Torres-Piles; Eduardo Ortega-Rincón
Journal:  Int J Mol Sci       Date:  2018-06-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.